Watchlist, Earnings, Economic Calender, Upgrades Downgrades, Gap Stocks, Day Trading

posted by:  elvis                     date:  5/17/2011

May 17, 2011
The manufacturing component of the industrial production report has been on fire. Will it extend its run to 10 straight monthly gains?


Notable earnings Before Tuesday's open: DKSHDHPQSKS,TJXVODWMT
Notable earnings After Tuesday's close: ADIDELL

Housing Starts
8:30 AM ET
8:55 AM ET
[Bullet11:30 AM ET

Up/Downgrades (ALLT, LFC, FWRD, SSS, FXCM, RAH, SYT)

Allot Communications (NASDAQ:ALLT) was upgraded to a Buy from Hold at ThinkEquity. The firm set its target price at $17.
China Life Insurance (NYSE:LFC) was upgraded to a Neutral at Credit Suisse.
Forward Air (NASDAQ:FWRD) was upgraded to Outperform from Neutral at Robert W. Baird. The firm raised its target price to $40 from $36m as it sees multiple catalysts supporting upside potential to estimates including firming industry rates, Core operating leverage, accelerated expedited freight demand, and acquisitions.
Sovran Self Storage (NYSE:SSS) was upgraded to a Neutral from Underperform at Macquarie.
FXCM (NASDAQ:FXCM) was downgraded to a Sell from Hold at Citigroup.
Ralcorp Holdings (NYSE:RAH), the food maker, was downgraded to a Hold from Buy at BB&T Capital Markets; saying a take out could yield $100, but upside is increasingly limited.
Syngenta (NYSE:SYT) was downgraded to Underperform from Market Perform at Bernstein.

Research Firms Initiate or Resume:
Astronics (NASDAQ:ATRO) was initiated with a Hold at EarlyBirdCapital.
Celldex Therapeutics (NASDAQ:CLDX) was initiated with Outperform and a target price of $6 at Oppenheimer. The firm said the company is developing rindopepimut for gliablastoma multiforme with EGFRvIII mutation as well as CDX-011, an antibody-drug conjugate for breast cancer. The firm believes that Celldex is overlooked by investors due to Pfizer's termination of partnership for rindopepimut, which was likely a result of corporate restructuring, and with peak US sales estimate of $350 mln, it believes that rindopepimut may not fit into Pfizer's growth strategy.
Hill-Rom (NYSE:HRC) was initiated with a Neutral at Goldman Sachs.
Immunomedics (NASDAQ:IMMU) was initiated with Outperform and a target price of $6 at Oppenheimer. The firm said the company is developing humanized antibodies for oncology and autoimmune indications. Its leading programs target pancreatic cancer, rheumatoid arthritis, and lupus, as well as multiple blood cancers.
Keryx Biopharmaceuticals (NASDAQ:KERX) was initiated with Outperform and a target price of $7 at Oppenheimer. The firm said the company has two assets in Phase III clinical trials, perifosine and Zerenex. Perifosine is being investigated in colorectal cancer and multiple myeloma. Pivotal study results are anticipated late this year. Firm notes Zerenex is a phosphate binder, with positive results from a short-term Phase III study already announced, and results from a pivotal long-term Phase III are anticipated in mid-2012.
MAKO Surgical (NASDAQ:MAKO) was initiated with a Buy at Goldman Sachs.
Nektar Therapeutics (NASDAQ:NKTR) was initiated with Outperform and a target price of $15 at Boenning & Scattergood. The firm believes commercial potential for NKTR-102 is not fully appreciated by investors.
Oncolytics Biotech (NASDAQ:ONCY) was initiated with Perform at Oppenheimer. The firm said the company is developing Reolysin, a naturally occurring reovirus, as a targeted therapy for cancer. Reovirus infects cancer cells due to suppression of cellular defense mechanisms in some tumor types, while the virus appears to be harmless to healthy tissue. Oncolytics has a broad clinical program investigating Reolysin in multiple tumors, and the company selected head and neck cancer as the lead indication.
PMC-Sierra (NASDAQ:PMCS) was resumed with a Hold and a target price of $8 at Auriga U.S.A. The firm said it expects strong sequential growth over the course of this year due to strength in storage, the Wintegra contribution, and recovering transport segment. However, firm says their estimates are lower than consensus for 2012 as they do not expect OTN to become meaningful before 2013, and their analysis also shows that growth in Wintegra and SAS in 2012 could be partially offset by declining Fiber Channel, SONET, T/E and Processor businesses.
Quaker Chemical (NYSE:KWR) was initiated with a Buy and a target price of $50 at KeyBanc Capital Markets. The firm believes Quaker is a quality specialty chemical company that has largely completed its turnaround efforts and is poised to generate 10%+ annual EPS growth over the next three years.
SandRidge Energy (NYSE:SD) was initiated with a Neutral and a target price of $12 at Robert W. Baird. The firm believes SandRidge provides a compelling oil growth story, with development of Permian and Mississippian plays, transforming the company into a more oily producer. The firm notes Neutral rating is underpinned by the lack of visibility into 2012 funding gap at this time.
SandRidge Mississippian Trust I (NYSE:SDT) was initiated with a Buy and a target price of $27.75 at Wunderlich. The firm believes SandRidge is a solid investment for several reasons, including: it offers a relatively high yield and the distribution should increase next year, it has a parent with a history of strong operating results, and once the trust's hedges expire, there is potential upside to the targeted distribution payout if commodity prices continue to rise. SandRidge Mississippian Trust was also initiated with Outperform at RBC Capital.
True Religion (NASDAQ:TRLG) was initiated with a Buy and a target price of $34 at The Benchmark Company. The firm said it expects revenue and earnings to grow as the Company continues to rollout Company-owned stores, drive comps through increased conversion and better product offerings, focus on international expansion, and improves its US Sales effort.
Gainers, losers:

No comments :

Post a Comment